Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Permethrin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Permethrin cream 5% | EXPERIMENTAL | Manufactured by Dr. Reddy's Laboratories, Ltd |
| Elimite™ Cream (permethrin) 5% | ACTIVE_COMPARATOR | Manufactured by Prestium Pharma, Inc |
| Name | Type | Description |
|---|---|---|
| Permethrin | DRUG | - |
Inclusion Criteria: 1. Signed Informed Consent that meets all criteria of current FDA regulations. 2. Male or non-pregnant, non-lactating female at least 2 years of age or older. 3. Diagnosis of active scabies by presence of a burrow and/or typical scabietic lesions at the classic sites of infestat...
Permethrin is a small molecule drug being developed for the treatment of scabies, a skin infestation caused by mites. It is currently in Phase 3 clinical development as a topical cream formulation.
Permethrin is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY.
Permethrin is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 3 trial has been completed.
Permethrin has one completed Phase 3 clinical trial, identified as NCT02572986. This study evaluated the therapeutic equivalence of generic Permethrin Cream 5% to Elimite in the treatment of scabies, enrolling 250 participants in the United States, El Salvador, and Panama.
Permethrin is being studied as a generic version of Elimite. The clinical trial NCT02572986 was designed to evaluate whether generic Permethrin Cream 5% is therapeutically equivalent to Elimite in treating scabies.